8-K: Cencora Reports Strong Q1 2025 Results, Raises Adjusted EPS Guidance

Cencora's first quarter fiscal year 2025 saw a 12.8% increase in revenue to $81.5 billion and the company raised its adjusted diluted EPS guidance for the full year.

Summary

• Cencora, Inc. reported its fiscal year 2025 first quarter results, with revenue reaching $81.5 billion, a 12.8% increase year-over-year.
• GAAP diluted EPS was $2.50, while adjusted diluted EPS increased by 13.7% to $3.73.
• The company has raised its adjusted diluted EPS guidance for fiscal year 2025 to a range of $15.25 to $15.55.
• The revenue increase was primarily driven by a 13.6% increase in the U.S. Healthcare Solutions segment.
• Gross profit increased by 3.6% to $2.6 billion, but gross profit as a percentage of revenue decreased by 28 basis points to 3.14% due to factors including increased sales of GLP-1 class products and lower COVID-19 vaccine sales.
• Operating expenses increased by 12.5% to $1.9 billion, mainly due to litigation and opioid-related expenses.
• Operating income decreased by 14.2% to $706.3 million.
• Net interest expense decreased by 31.1% to $27.9 million.
• The effective tax rate was 20.4% compared to 23.0% in the prior year quarter.
• The company completed the acquisition of Retina Consultants of America (RCA) on January 2, 2025.
• Revenue growth is now expected to be in the range of 8% to 10%.
• Adjusted consolidated operating income growth is projected to be between 11.5% and 13.5%.
• Net interest expense is expected to be in the range of $290 million to $310 million.
• Weighted average diluted shares outstanding are expected to be under 196 million.
• A quarterly cash dividend of $0.55 per common share was declared, payable on March 3, 2025.
• The company's Board of Directors declared a quarterly cash dividend of $0.55 per common share, payable March 3, 2025, to stockholders of record at the close of business on February 14, 2025.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, increased EPS, and raised guidance. While there are some challenges related to operating expenses and gross profit margins, the overall tone is optimistic.

Positives

• Cencora experienced significant revenue growth of 12.8% year-over-year.
• Adjusted diluted EPS increased by 13.7%, indicating improved profitability.
• The company raised its adjusted diluted EPS guidance for the full fiscal year.
• The U.S. Healthcare Solutions segment demonstrated strong growth with a 13.6% revenue increase.
• The acquisition of RCA is expected to contribute to future growth and strengthen Cencora's position in specialty healthcare.
• The company declared a quarterly cash dividend of $0.55 per common share.

Negatives

• GAAP diluted EPS decreased by 16.1% compared to the prior year.
• Gross profit as a percentage of revenue decreased by 28 basis points.
• Operating expenses increased significantly due to litigation and opioid-related expenses.
• Operating income decreased by 14.2%.

Risks

• Litigation and opioid-related expenses continue to impact operating expenses.
• The decline in gross profit margin in the U.S. Healthcare Solutions segment due to increased sales of lower-margin products and decreased COVID-19 related sales could affect future profitability.
• The company's forward-looking statements are subject to various risks and uncertainties as detailed in their SEC filings.

Future Outlook

Cencora expects revenue growth to be in the range of 8% to 10%, and adjusted diluted EPS to be in the range of $15.25 to $15.55 for fiscal year 2025. Adjusted consolidated operating income growth is expected to be between 11.5% and 13.5%. Net interest expense is projected to be between $290 million and $310 million. Weighted average diluted shares outstanding are expected to be under 196 million.

Management Comments

• Robert P. Mauch, President and Chief Executive Officer of Cencora, stated that Cencora delivered an excellent start to fiscal 2025 by focusing on advancing core capabilities and enhancing value proposition.
• Mauch also mentioned that the acquisition of Retina Consultants of America drives forward their leadership in Specialty.

Industry Context

Cencora's results reflect the ongoing trends in the pharmaceutical and healthcare industries, including the increasing demand for specialty products and the impact of GLP-1 drugs on revenue and margins. The acquisition of RCA aligns with the industry's focus on expanding into specialized healthcare services.

Comparison to Industry Standards

• Cencora's revenue growth of 12.8% is strong compared to other major pharmaceutical distributors like McKesson and Cardinal Health, which have seen more modest growth.
• The adjusted EPS growth of 13.7% also positions Cencora favorably against its peers.
• The acquisition of RCA is similar to moves by other healthcare companies to diversify into higher-margin specialty services, such as CVS Health's acquisition of Aetna.

Stakeholder Impact

• Shareholders will benefit from the increased EPS and dividend payments.
• Customers will benefit from Cencora's enhanced services and solutions.
• Employees will be part of a growing and successful organization.

Next Steps

• Cencora management will attend the Leerink Partners Global Healthcare Conference in March 2025.
• Investors can access replays of the conference call and slide presentation on the company's website.

Key Dates

Keywords

Cencora, earnings, revenue, EPS, guidance, pharmaceutical, healthcare, acquisition, RCA, dividend